Connect with us

Technology

Beckman Coulter Diagnostics Expands Alzheimer’s Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay

Published

on

CE-marked Access p-Tau217 blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline across Europe

Brain Derived pTau217 RUO assay selectively detects brain-derived pTau217 unlocking new neurodegenerative insights through high-specificity research of amyloid and tau pathology

Powered by the DxI 9000 Immunoassay Analyzer, this expanding portfolio enables laboratories to
provide diverse testing capabilities within a single, high-throughput, high sensitivity solution

BREA, Calif., July 7, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer’s Association International Conference (AAIC) 2026 in London.

The CE Mark represents a significant milestone in expanding access to blood-based p-Tau217 testing in Europe and additional CE-recognizing markets, supporting laboratories and clinicians with a scalable, automated solution. Building on this clinical progress, the newly launched RUO assay is designed to further advance research into disease biology. Both assays are enabled by the DxI 9000 Immunoassay Analyzer, ensuring laboratories can efficiently manage clinical and research tests on a single high-precision analyzer.

Scaling Access to Alzheimer’s Disease Blood Testing with CE-Marked, Automated p-Tau217 Assay

The new CE Marked assay measures phosphorylated tau (p-Tau217), a well-established biomarker associated with Alzheimer’s disease, enabling scalable assessment in routine clinical settings. Blood-based approaches can complement existing diagnostic pathways by offering a more accessible, operationally scalable method for evaluating Alzheimer’s-related pathology within laboratory workflows.

“Our CE-marked Access p-Tau217 assay brings a well-established Alzheimer’s biomarker into routine clinical workflows, enabling laboratories to scale blood-based evaluation of disease pathology more efficiently,” said Dr. Chris Bird, Chief Medical Officer at Beckman Coulter Diagnostics. “By making testing more accessible and operationally scalable, it helps integrate biomarker-based assessment into everyday clinical practice.”

Beckman Coulter Diagnostics developed the Access p‑Tau217 assay using AlzPath’s antibody, cited in more than 200 peer‑reviewed publications, underscoring strong scientific validation. As demand for Alzheimer’s disease diagnostics grows, blood‑based testing will play an increasingly important role in enabling consistent evaluation across clinical settings. This milestone marks the translation of validated biomarker science into Beckman Coulter’s first clinical, blood‑based assay for amyloid pathology in patients with signs and symptoms of cognitive decline, accelerating the path from research insight to real‑world use.

Introducing High-Specificity Brain-Derived pTau217 Assay for Research Use

In addition to the CE-marked IVD assay, Beckman Coulter Diagnostics is introducing its Access BD-pTau217 RUO assay, designed to selectively detect the short form (or low molecular weight) pTau217 in blood samples using the DxI 9000 Analyzer. By targeting the short form of pTau217 originating in the brain, the new research assay is designed to enhance biological specificity and provide precise characterization of central nervous system phosphorylated Tau217 signals in blood.

“By focusing on brain-derived pTau217, this assay is designed to deliver a higher level of biological specificity, helping researchers more precisely identify tau pathology in blood most relevant to their studies,” said Dr. Jeremiah Hinson, Chief Scientific Officer for Neurodegenerative Diseases at Danaher . “This increased specificity can bolster confidence in studying Alzheimer’s disease staging and support new insights into the biological inflection points that define how the disease evolves.”

Early research findings suggest that higher biological specificity may help improve interpretability of biomarker detection in complex research datasets and support clearer differentiation of tau-related pathology in Alzheimer’s disease.

“In the AIBL Study of Ageing, plasma pTau217 demonstrated strong performance as a blood‑based marker of Alzheimer’s pathology,” said James Doecke, PhD, Principal Research Scientist, Commonwealth Scientific and Industrial Research Organisation and the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. “When evaluated alongside amyloid and tau PET imaging, brain‑derived pTau217 showed additional biological specificity, particularly for research focused on tau‑related staging. These findings reinforce the role of pTau217 as a cornerstone biomarker while highlighting the potential value of higher biological specificity for improving clarity in Alzheimer’s disease research.”

Advancing Alzheimer’s Disease Testing Through the DxI 9000 Immunoassay System

Beckman Coulter Diagnostics is advancing its Alzheimer’s disease portfolio on the DxI 9000 Analyzer, a highly sensitive, scalable platform designed to detect low-abundance biomarkers with consistency. By enabling both the CE-marked Access p-Tau217 assay and the Access BD-pTau217 (RUO), as well as existing Access GFAP (RUO), Access BD-Tau (RUO), Access NfL (RUO), Access Beta-Amyloid 1-42 (RUO) and Access apoE ε4 (RUO) assays to run on a common platform, laboratories can integrate diverse testing capabilities within a consistent, high-throughput workflow.

“High-sensitivity detection, robust assays, and operational scalability are critical as blood-based biomarkers become more widely adopted,” said Dr. Nick Culshaw, Vice President and Managing Director, Clinical Chemistry and Immunoassay Business at Beckman Coulter Diagnostics. “By anchoring our Alzheimer’s disease portfolio on the DxI 9000 Analyzer, we are enabling laboratories to access an expanding set of biomarker insights, from clinical assessment to research applications, within a single system.”

The DxI 9000 Analyzer combines analytical sensitivity with operational flexibility, allowing laboratories to support a growing range of biomarker applications, from routine clinical evaluation to advanced research into disease biology, without compromising performance or efficiency. This unified platform approach helps ensure consistency in assay execution while enabling expansion into emerging markers across neurodegenerative diseases as scientific understanding evolves.

Beckman Coulter Diagnostics at AAIC 2026

At AAIC 2026 in London, Beckman Coulter Diagnostics will highlight new data advancing blood-based testing for Alzheimer’s disease through a focused program of scientific presentations and expert engagement.

The company will present five posters on pTau217 and novel biomarker approaches, including data demonstrating improved detection of Alzheimer’s pathology and enhanced performance using biomarker ratios and next-generation assays. Featured research spans clinical utility, disease staging and assay innovation, as well as late-breaker findings on pTau217/Aβ42 and BD‑Tau ratio approaches.

Key on-site engagements include:

Enabling Alzheimer’s Biological Staging with Blood Based Biomarkers, featuring James Doecke, PhD, and Charbel Abou-Diwan, PhD, Senior Director, Medical & Scientific Affairs, Beckman Coulter Diagnostics, July 13, 10:30–11:00 AMImproving real-world representation in Alzheimer’s disease research and treatment, Opening remarks by Jeremiah Hinson, M.D., Ph.D., followed by Sid E. O’Bryant, Ph.D.; Suzanne Craft, Ph.D.; Carlos Cruchaga, Ph.D.; Michelle Mielke, Ph.D.; Charlotte Teunissen, Ph.D.; and Michael Weiner, M.D. July 13, 12:30–1:45 PM 

Attendees can also visit the Beckman Coulter Diagnostics booth #921 to connect with experts and explore how high-throughput immunoassay platforms are supporting scalable adoption of blood-based biomarker testing.

About Beckman Coulter. Inc.

Beckman Coulter Diagnostics is a global leader in advanced diagnostics, helping laboratories transform insight into impact through science, technology, and collaboration. For more than 90 years, the company has challenged convention to elevate the role of the diagnostic laboratory, accelerating ideas from discovery to real world clinical outcomes. Guided by its mission to Relentlessly Reimagine Healthcare, One Diagnosis at a Time, Beckman Coulter Diagnostics delivers trusted solutions for complex clinical testing across hospitals, reference laboratories, and physician office settings worldwide, supported by an extensive clinical menu, scalable automation, actionable informatics, and lab performance optimization services. Part of Danaher, a global science and technology innovator, Beckman Coulter Diagnostics draws on a connected network of specialized companies—combining shared capabilities, scale, and expertise to help solve some of healthcare’s most complex challenges, together.  Headquartered in Brea, California, the company employs more than 11,000 associates globally.

Follow and connect with Beckman Coulter via LinkedInX, and Facebook

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

The Access p‑Tau217 assay is CE‑marked under IVDR (EU) 2017/746 (CE 2797)

© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. 3092-GBL-EN

View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-expands-alzheimers-portfolio-with-ce-marked-p-tau217-blood-test-and-new-high-specificity-research-assay-302818858.html

SOURCE Beckman Coulter Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Insurify Exceeds 250 Million Auto Insurance Quotes Served

Published

on

By

The milestone reflects Insurify’s industry dominance as an insurance comparison platform that helps Americans compare quotes, saving consumers up to $1,100* on their auto insurance policy.

CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ — Insurify, the leading online insurance comparison platform, announced today that its total number of real-time auto insurance quotes served to American consumers has reached a landmark 250 million. With a quote database that’s more than three times larger than the publicly reported volume of major competitors, Insurify empowers auto insurance shoppers to compare quotes and buy policies entirely online.

Since its launch in 2016, millions of drivers have turned to Insurify to find better coverage at a lower price. In the last year alone, Insurify users saved up to $1,100* on their auto insurance policy, annually.

“Reaching this landmark speaks to the trust insurance shoppers place in Insurify,” said Snejina Zacharia, founder and co-CEO of Insurify. “This volume of quotes enables Insurify to provide insurance shoppers with the most accurate quotes possible, and provide data-driven consumer insights.”

Insurify is also the go-to source for major media outlets needing verified auto insurance quote data. Its robust database spans all 50 states, Washington, D.C., including metropolitan and rural areas, and multiple coverage levels, and driver profiles.

How Insurify differs from lead-generation ‘comparison’ sites

Insurify’s 250-million-quote database of real-time insurance quotes sets it apart from lead-generation sites, which gather information from insurance shoppers and then sell it to third parties.

Every auto insurance quote Insurify provides comes from its integrations with more than 120 partner insurance companies. Quotes reflect real-time auto insurance rates, and are personalized to each driver’s actual location, driver profile, driving record, credit history (where state law permits it), and additional rating factors insurance companies use when setting rates.

Leading in data-driven consumer insights

The scale of Insurify’s database enables precise national, state and city-level analysis that reflects an authentic consumer experience. Insurify translates these analyses into relatable, highly digestible consumer-focused insights that help drive insurance shoppers’ decision making.

This empowers consumers to:

Track insurance costs by car modelKnow when auto insurance rates dropGet insight into how DUIs, accidents, and tickets, change rates over timeUnderstand how factors like, age, gender and credit history, affect rates

“When drivers come to our platform they are not just shopping for insurance. They are trying to find more room in their budget for groceries, housing costs, and other necessities,” Zacharia said. “To meet the diverse needs of all U.S. consumers, Insurify partners with national, regional, and niche insurers. We want someone who comes to our platform to find a policy that meets their needs and fits their budget.”

About Insurify:

Insurify is America’s top-rated online insurance marketplace, offering a secure, spam-free way to compare and buy coverage. With a network of 120-plus carrier partners, Insurify empowers consumers to compare auto, home, pet, and renters insurance in minutes, online or with the help of a licensed agent. Since 2016, Insurify’s AI-powered technology has served over 250 million quotes. By using Insurify, customers can save hundreds of dollars annually, with some saving up to 50% on their premiums. In 2026, Insurify expanded its innovation with Insurify Car, providing liability-only coverage through flexible, weekly payment options underwritten by its insurance carrier partners.

* Average potential savings based on initial quotes received by 31,051 customers seeking insurance through Insurify. Actual savings may vary depending on state of residence, individual circumstances, coverage selections, and insurance provider. Savings and lowest rates do not reflect typical results.

For more information, contact:
jessica.edmondson@insurify.com
Press@Insurify.com
https://Insurify.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insurify-exceeds-250-million-auto-insurance-quotes-served-302820045.html

SOURCE INSURIFY, Inc.

Continue Reading

Technology

Alta Raises $25M to Redefine the Go-to-Market Architecture for Revenue Teams

Published

on

By

By transforming the GTM stack, Alta’s AI team brings a learning curve managers can only dream about

TEL AVIV, Israel, July 8, 2026 /PRNewswire/ — Alta, the AI System of Actions for go-to-market teams, today announced $25 million in Series A funding. The round was led by IN Venture, with participation from Mindset Ventures, Skywell Capital, LeumiTech77 and existing investors Entrée Capital, Target Global, and Verissimo Ventures, along with prominent angel investors and scout funds.

Alta will use the funding to accelerate growth by expanding its team globally, growing its customer base, and enhancing the platform – adding new data, CRM, and advertising integrations, as well as introducing agents for account management and cross-selling.

Alta hit its first million in revenue within months of commercializing and is on track for 800% revenue growth this year. Its platform is already being used by Snowflake, Deel, Atlassian, and Atoms, as well as hundreds of businesses, from Fortune 500 companies to SMBs.

For decades, GTM has run on “systems of record”: CRMs and data warehouses storing information until a human acts on it and dozens of disjointed tools that don’t communicate.  As companies increasingly implement AI, the industry has bet on AI agents as point solutions for automating outbound or inbound GTM at scale. The results, however, often fall short, and can even exacerbate problems by scaling broken playbooks. Even though AI allows teams to generate more activity, pipelines remain flat, lead quality has fallen, and reply rates have dropped as buyers’ inboxes are filled with generic, monotonous, AI-generated outreach.

Industry leaders like Salesforce and HubSpot have introduced agent-enablement layers through APIs, MCP tools, and CLI interfaces, underscoring a broader race to add intelligence to systems originally designed for data storage and workflow management. But retrofitting intelligence onto legacy architectures is fundamentally different from building an intelligence-native platform from the ground up – one that understands business context, orchestrates every customer and operational touchpoint, and continuously compounds value through real-world outcomes. Recognizing this need, Alta designed and built its solutions.

Alta tackles the challenge of deploying AI agents by first building a “Company Brain” that serves as a centralized intelligence layer that maps exactly how a business’s GTM engine works. Instead of relying on a fragmented stack of disconnected software, Alta replaces them with a single, coordinated network of AI agents that learn from every action. Powered by this shared “Brain” and fueled by more than 50 data sources and hundreds of buying signals, these agents orchestrate and act on existing systems of record, collaborating and evolving as a single unit with every single interaction. The platform partners with Salesforce, HubSpot, IBM, and Google, and connects to 60+ GTM tools, including Attio and Clay, enabling Alta to run on top of the stack teams already in use rather than locking them into a closed box.

“Before the cloud, every company building software racked and maintained its own servers,” said Stav Levi-Neumark, CEO and Co-founder of Alta. “We’re doing for go-to-market what AWS did for infrastructure and the cloud: transforming a stack of cobbled-together tools that never communicated into one system that simply runs well, learns, and drives revenue pipelines and sales.”

“The market spent three years adding tools to the sales stack. The team at Alta went the other way and built the intelligence layer the whole stack was missing,” said Eitan Naor, Managing Partner at IN Venture (Member of Sumitomo Corporation’s Venture Group). “Alta isn’t competing in a category — it’s defining one. That’s why we wanted to lead this round, and why we’re excited to introduce Alta to Japan and Southeast Asia, backed by Sumitomo’s global reach.”

“Having worked closely with Stav at monday.com, I knew firsthand her rare ability to turn complex data into explosive growth,” said Avi Eyal, Managing Partner at Entrée Capital. The Alta team is not just building another AI feature; they are fundamentally redefining GTM architecture. Watching them scale from inception to this milestone proves that the market is starving for a single, intelligent system of action.”

About Alta

Alta is the AI System of Actions for go-to-market. We run your GTM, replacing the fragmented sales stack with coordinated AI agents that share one Company Brain and compound with every interaction. Founded in 2023 by Stav Levi-Neumark and Tom Hoffen, both ex-monday.com, and serial entrepreneur Mor Shabtai, Alta handles prospecting, research, multi-channel outbound, inbound qualification, AI calling, and continuous optimization. Alta hit its first million in revenue within months of commercializing and is on track for 800% revenue growth this year. Its customers include revenue teams at Snowflake, Deel, Atlassian, Atoms, Riverside, and Sabio Group. Learn more at altahq.com.

Contact:

Rebecca Ash
rebecca@gova10.com

View original content:https://www.prnewswire.com/news-releases/alta-raises-25m-to-redefine-the-go-to-market-architecture-for-revenue-teams-302820618.html

SOURCE Alta

Continue Reading

Technology

PTC to Announce Fiscal Q3’26 Results on Wednesday, July 29, 2026

Published

on

By

BOSTON, July 8, 2026 /PRNewswire/ — PTC (NASDAQ: PTC) will release its fiscal 2026 third quarter results on Wednesday, July 29th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, July 29th at 5 p.m. Eastern Time (ET). The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the company’s website at PTC Investor Relations.

What:

 PTC Fiscal Q3’26 Conference Call and Webcast

When:

 Wednesday, July 29, 2026 5:00 p.m. ET

Webcast:

 Register Here

Replay:

 To access the replay via webcast, please visit this page.

Please note that statements made on the conference call and webcast are as of the date of the conference call and webcast and PTC does not assume any obligation to update any statements made live or the archived call. Matters discussed may include forward-looking statements about PTC’s anticipated financial results and growth, as well as about the development of products and markets, which are based on current plans and assumptions. Actual results in future periods may differ materially from current expectations due to a number of risks and uncertainties, including those described from time to time in reports filed by PTC with the U.S. Securities and Exchange Commission, including PTC’s most recent reports on Form 10-K and 10-Q.

About PTC

PTC (NASDAQ: PTC) is a global software company enabling manufacturers and product companies to digitally transform how they design, manufacture, and service the physical products the world relies on. Headquartered in Boston, Massachusetts, PTC employs over 7,000 people and supports more than 30,000 customers globally. For more information, please visit www.ptc.com.

Investor Contact

Michael Maguire
mmaguire@ptc.com
investor@ptc.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-to-announce-fiscal-q326-results-on-wednesday-july-29-2026-302815708.html

SOURCE PTC Inc.

Continue Reading

Trending